Cargando…

Sunitinib in combination with trastuzumab for the treatment of advanced breast cancer: activity and safety results from a phase II study

BACKGROUND: This phase II study evaluated the efficacy and safety/tolerability of sunitinib plus trastuzumab in patients with HER2-positive advanced breast cancer (ABC). METHODS: Eligible patients received sunitinib 37.5 mg/day and trastuzumab administered either weekly (loading, 4 mg/kg; then weekl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bachelot, Thomas, Garcia-Saenz, Jose A, Verma, Sunil, Gutierrez, Maya, Pivot, Xavier, Kozloff, Mark F, Prady, Catherine, Huang, Xin, Khosravan, Reza, Wang, Zhixiao, Cesari, Rossano, Tassell, Vanessa, Kern, Kenneth A, Blay, Jean-Yves, Lluch, Ana
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3995914/ https://www.ncbi.nlm.nih.gov/pubmed/24606768 http://dx.doi.org/10.1186/1471-2407-14-166

Ejemplares similares

Population pharmacokinetics–pharmacodynamics of sunitinib in pediatric patients with solid tumors
por: Wang, Erjian, et al.
Publicado: (2020)

Extrapolation of pharmacokinetics and pharmacodynamics of sunitinib in children with gastrointestinal stromal tumors
por: Khosravan, Reza, et al.
Publicado: (2021)

Can we establish a hierarchy among trastuzumab biosimilar candidates?
por: Pivot, Xavier, et al.
Publicado: (2018)

A time and motion study of subcutaneous versus intravenous trastuzumab in patients with HER2‐positive early breast cancer
por: De Cock, Erwin, et al.
Publicado: (2016)

Chemotherapeutic Drugs and Mitochondrial Dysfunction: Focus on Doxorubicin, Trastuzumab, and Sunitinib
por: Gorini, Stefania, et al.
Publicado: (2018)

Effect of gastrointestinal resection on sunitinib exposure in patients with GIST
por: de Wit, Djoeke, et al.
Publicado: (2014)

Population Pharmacokinetic/Pharmacodynamic Modeling of Sunitinib by Dosing Schedule in Patients with Advanced Renal Cell Carcinoma or Gastrointestinal Stromal Tumor
por: Khosravan, Reza, et al.
Publicado: (2016)

Corrigendum to “Chemotherapeutic Drugs and Mitochondrial Dysfunction: Focus on Doxorubicin, Trastuzumab, and Sunitinib”
por: Gorini, Stefania, et al.
Publicado: (2019)

Population Pharmacokinetics of Sunitinib and its Active Metabolite SU012662 in Pediatric Patients with Gastrointestinal Stromal Tumors or Other Solid Tumors
por: Wang, Erjian, et al.
Publicado: (2021)

Sunitinib in pediatric patients with advanced gastrointestinal stromal tumor: results from a phase I/II trial
por: Verschuur, Arnauld C., et al.
Publicado: (2019)

An exploratory study of sunitinib plus paclitaxel as first-line treatment for patients with advanced breast cancer
por: Kozloff, M., et al.
Publicado: (2010)

Adjuvant Trastuzumab Is Required in Human Epidermal Growth Factor Receptor 2-Positive Node-Negative Breast Cancer Patients Regardless of Tumour Size
por: Bender, Laura, et al.
Publicado: (2020)

Trastuzumab in the adjuvant setting: concurrent or sequential? It takes two to tango!
por: Verma, Sunil
Publicado: (2008)

Biologic Drug Quality Assurance to Optimize HER2 + Breast Cancer Treatment: Insights from Development of the Trastuzumab Biosimilar SB3
por: Lüftner, Diana, et al.
Publicado: (2020)

Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer
por: Barrios, Carlos H., et al.
Publicado: (2010)

Sorafenib and sunitinib: A dermatologist's perspective
por: Pragasam, Vijendran, et al.
Publicado: (2014)

The multitargeted receptor tyrosine kinase inhibitor sunitinib induces resistance of HER2 positive breast cancer cells to trastuzumab-mediated ADCC
por: Guti, Eliza, et al.
Publicado: (2022)

Evaluating the clinical effectiveness and safety of various HER2-targeted regimens after prior taxane/trastuzumab in patients with previously treated, unresectable, or metastatic HER2-positive breast cancer: a systematic review and network meta-analysis
por: Paracha, Noman, et al.
Publicado: (2020)

Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer
por: Perez, Edith A., et al.
Publicado: (2019)

Trastuzumab Emtansine With or Without Pertuzumab Versus Trastuzumab Plus Taxane for Human Epidermal Growth Factor Receptor 2–Positive, Advanced Breast Cancer: Primary Results From the Phase III MARIANNE Study
por: Perez, Edith A., et al.
Publicado: (2017)

Correction to: Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer
por: Perez, Edith A., et al.
Publicado: (2019)

Cardiac management during adjuvant trastuzumab therapy: recommendations of the Canadian Trastuzumab Working Group
por: Mackey, J.R., et al.
Publicado: (2008)

Sunitinib in the treatment of gastrointestinal stromal tumor: patient selection and perspectives
por: Mulet-Margalef, Nuria, et al.
Publicado: (2016)

Soluble KIT correlates with clinical outcome in patients with metastatic breast cancer treated with sunitinib
por: Keyvanjah, Kiana, et al.
Publicado: (2012)

Sunitinib Induced Immune Thrombocytopenia
por: Shekarriz, Ramin, et al.
Publicado: (2015)

Sunitinib: the antiangiogenic effects and beyond
por: Hao, Zhonglin, et al.
Publicado: (2016)

Reversal of Cushing Pigmentation by Sunitinib
por: Iwasaki, Yorihiro, et al.
Publicado: (2019)

Sunitinib: Colitis: case report
Publicado: (2022)

Cardiotoxicity is mitigated after a supervised exercise program in HER2-positive breast cancer undergoing adjuvant trastuzumab
por: Jacquinot, Quentin, et al.
Publicado: (2022)

A phase 2 randomized trial to evaluate the impact of a supervised exercise program on cardiotoxicity at 3 months in patients with HER2 overexpressing breast cancer undergoing adjuvant treatment by trastuzumab: design of the CARDAPAC study
por: Jacquinot, Quentin, et al.
Publicado: (2017)

Safety and efficacy of adjuvant subcutaneous trastuzumab in human epidermal growth factor receptor 2-positive early breast cancer: Final results of the SafeHER study
por: Gligorov, Joseph, et al.
Publicado: (2022)

Metastatic Thymic Carcinoma with Long Survival After Treatment with Sunitinib
por: Cabezón-Gutiérrez, Luis, et al.
Publicado: (2018)

Beliefs and behavior regarding e-cigarettes in a large cross-sectional survey
por: Couraud, Sébastien, et al.
Publicado: (2018)

Cost Effectiveness of Trastuzumab for Management of Breast Cancer in India
por: Gupta, Nidhi, et al.
Publicado: (2020)

Sunitinib for advanced renal cell cancer
por: Coppin, Chris
Publicado: (2008)

Combining radiotherapy with sunitinib: lessons (to be) learned
por: Kleibeuker, Esther A., et al.
Publicado: (2015)

Sunitinib resistance in renal cell carcinoma
por: Morais, Christudas
Publicado: (2014)

Sunitinib-Induced Acute Liver Failure
por: Aqsa, Anum, et al.
Publicado: (2021)

Resistance to Trastuzumab
por: Vivekanandhan, Sneha, et al.
Publicado: (2022)

Trastuzumab-induced thrombocytopenia after eight cycles of trastuzumab treatment
por: Zhou, Qiong, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_merpkolq3mrofg56mgin9rsrri